SEA 0400

Drug Profile

SEA 0400

Latest Information Update: 15 Sep 2004

Price : $50

At a glance

  • Originator Taisho Pharmaceutical
  • Class Aniline compounds; Anti-ischaemics; Phenyl ethers; Small molecules
  • Mechanism of Action Sodium-calcium exchanger inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Cerebral ischaemia; Reperfusion injury

Most Recent Events

  • 15 Sep 2004 No development reported - Preclinical for Cerebral ischaemia in Japan (unspecified route)
  • 15 Sep 2004 No development reported - Preclinical for Reperfusion injury in Japan (unspecified route)
  • 16 Apr 2003 A preclinical study has been added to the Ischemic Heart Disease pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top